Patient Information: Summary of Product Characteristics
Doptelet 20 mg, film-coated tablets
avatrombopag
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Doptelet contains the active substance avatrombopag. It belongs to a group of medicines known as thrombopoietin receptor agonists.
Doptelet is used in adults with chronic liver disease to treat low platelet counts (thrombocytopenia) before undergoing a medical procedure where there is a risk of bleeding.
Doptelet is used to treat adults with low platelet counts due to primary chronic immune thrombocytopenia (ITP) when previous treatment for ITP (such as corticosteroids or immunoglobulins) has not worked well enough.
Doptelet helps increase the platelet count in the blood. Platelets are blood cells that help the blood to clot to reduce or prevent bleeding.
Do not take Doptelet:
Warnings and precautions
Talk to your doctor or pharmacist before starting Doptelet if:
It is possible that the risk of blood clots may increaseas you get older if:
If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking Doptelet.
Blood tests for platelet count
If you stop taking Doptelet, your platelet count is likely to decrease to the level before treatment or even below that, with a risk of bleeding. This can happen within days. Your platelet count will be monitored and your doctor will discuss the appropriate precautions with you.
Tests to check the bone marrow
In people with bone marrow problems, medicines like Doptelet may worsen these problems. Signs of changes in the bone marrow may appear as abnormal blood test results. Your doctor may also perform tests to directly examine the bone marrow during treatment with Doptelet.
Children and adolescents
Do not give Doptelet to people under 18 years of age. The safety and efficacy of this medicine in this age group are not known.
Other medicines and Doptelet
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If you are taking other medicines for ITP, you may need to take them in lower doses or stop them during treatment with Doptelet.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Doptelet is not recommended during pregnancy or in women of childbearing potential not using contraception.
If you are breastfeeding, ask your doctor or pharmacist for advice before taking Doptelet. This medicine may pass into breast milk. Your doctor will decide whether the benefits of breastfeeding are greater than the possible risks to the baby during this period.
Driving and using machines
Doptelet is not expected to affect your ability to drive, ride a bicycle or use tools or machines.
Doptelet contains lactose
Doptelet contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to some sugars, talk to them before taking this medicine.
Follow exactly the instructions given to you by your doctor or pharmacist. If you are not sure, talk to your doctor or pharmacist again.
If you have chronic liver disease and a low platelet count, your medical procedure should be scheduled 5 to 8 days after the last dose of Doptelet.
If you have chronic ITP, your doctor will tell you how much Doptelet to take and how often.
How much to take
If you have chronic liver disease and are scheduled for an invasive procedure
If you have chronic ITP
How to take this medicine
If you have chronic liver disease and a low platelet count
If you have chronic ITP
If you take more Doptelet than you should
If you forget to take Doptelet
If you stop taking Doptelet
Take Doptelet for as long as your doctor has told you. Do not stop taking Doptelet unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
See your doctor or pharmacist if you notice any of the following side effects:
The following side effects have been reported in patients with chronic liver disease taking Doptelet:
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency not known(cannot be estimated from the available data)
The following side effects have been reported in patients with chronic ITP taking Doptelet:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Common side effects that may be detected in blood tests
Uncommon(may affect up to 1 in 100 people)
Uncommon side effects that may be detected in blood tests
Frequency not known(cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What is in Doptelet
Tablet core: lactose monohydrate (see section 2 ‘Doptelet contains lactose’); microcrystalline cellulose [E460(i)]; crospovidone type B [E1202]; colloidal anhydrous silica [E551]; magnesium stearate [E470b].
Tablet coating: polyvinyl alcohol [E1203]; talc [E553b]; macrogol 3350 [E1521]; titanium dioxide [E171]; yellow iron oxide [E172].
Appearance of Doptelet and contents of the pack
The 20 mg film-coated tablets (tablets) of Doptelet are light yellow, rounded at the top and bottom, and have the letters «AVA» embossed on one side of the tablet and the number «20» on the other.
The tablets are supplied in cartons containing one or two aluminum blisters. Each blister contains 10 or 15 tablets.
Marketing authorisation holder
Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm
Sweden
Manufacturer
Swedish Orphan Biovitrum AB (publ)
Strandbergsgatan 49
Stockholm 112 51
Sweden
Date of last revision of this leaflet: 02/2024.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.